2025-10-11 - Analysis Report
Okay, here's a report based on the provided data, formatted for readability and analysis.

**Hims & Hers Health Inc (HIMS) Stock Analysis**

Hims & Hers Health Inc (HIMS) is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals.

**1. Performance vs. S&P 500 (VOO)**

*   **HIMS Cumulative Return:** 261.57%
*   **VOO Cumulative Return:** 73.04%
*   **Absolute Divergence (Current):** 207.9
*   **Relative Divergence:** 72.1

**Analysis:** HIMS has significantly outperformed the S&P 500 (VOO) over the observed period. The relative divergence of 72.1 suggests that while HIMS's performance has been exceptional, it's positioned in the upper range of its historical performance relative to VOO.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
|------------|---------|-------|---------|-------|--------|
| 2019-2021  | -42.0%  | 74.4% | -81.0%  | 0.0   | 1.5    |
| 2020-2022  | -19.0%  | 78.6% | -18.0%  | -0.0  | 1.4    |
| 2021-2023  | -65.0%  | 78.6% | -67.0%  | -0.1  | 2.0    |
| 2022-2024  | 119.0%  | 79.4% | 98.0%   | -0.0  | 5.5    |
| 2023-2025  | 266.0%  | 80.8% | 203.0%  | 0.1   | 12.5   |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** The CAGR fluctuates significantly, with negative values in earlier periods and very high positive values in the recent 2022-2025 period. This indicates high volatility and recent strong growth.
*   **MDD (Maximum Drawdown):** The MDD is consistently high, indicating substantial risk and potential for significant losses during downturns.
*   **Alpha:** Alpha measures the excess return compared to the benchmark. The recent periods show very high alpha, indicating significant outperformance.
*   **Beta:** Beta measures volatility relative to the market. The beta values are close to 0, suggesting HIMS's price is not strongly correlated with the overall market.
*   **Cap(B):** Market capitalization has increased significantly, particularly in the most recent period, reflecting investor confidence and company growth.

**2. Recent Stock Price Movement**

*   **Current Price:** 55.14
*   **Last Market Data:** Price: 55.11, Previous Close: 58.25, Change: -5.39
*   **5-Day Moving Average:** 55.72
*   **20-Day Moving Average:** 55.47
*   **60-Day Moving Average:** 52.11

**Analysis:**  The stock price has recently experienced a notable drop (-5.39 compared to the previous close), which warrants attention. The 5-day and 20-day moving averages are close, suggesting a consolidation phase. The 60-day moving average is lower, indicating an upward trend over the past two months, despite the recent dip.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 45.10
*   **PPO:** -0.28
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (17 shares - Very Safe - MRI:0.90) Monthly invest 1.3% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Recent (20-day) Relative Divergence Change:** 2.6 (+) (Short-term Increase)
*   **Expected Return:** 2.0% (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI suggests a high investment recommendation, indicating a favorable risk-reward profile.
*   The RSI of 45.10 is neutral, not indicating overbought or oversold conditions.
*   The PPO is slightly negative, suggesting potential short-term weakness but within a normal range.
*   The hybrid signal of 100% cash buy recommendation suggest it's good to enter the market.
*   The positive change in relative divergence suggests short-term upward momentum.
*   The expected return of 2.0% (over the S&P 500) is a long-term perspective.
*   The significant price drop from the last market day (change: -5.39) indicates a potential short-term issue.

**4. Recent News & Significant Events**

*   **[2025-10-10] Taking Advantage Of Hims & Hers Stock Volatility:** Suggests the stock may be suitable for traders looking for short-term opportunities.
*   **[2025-10-09] How Hims & Hers founder Joe Spector turned 10 failures into $1B idea:** Highlights the founder's resilience and the company's growth story, potentially boosting investor confidence.
*   **[2025-10-09] One founder's 3 rules for breaking into a complex market:** Showcases the company's strategic approach and potential competitive advantages.
*   **[2025-10-09] Hims & Hers Expands Personalized Care Access Via Telehealth Platform:** Positive news indicating growth and expansion of services, which could drive revenue.
*   **[2025-10-09] Customers Say Care Through Hims & Hers Matches, or Beats, the Doctor’s Office:** Demonstrates strong customer satisfaction and potential for continued adoption.

**4-2. Analyst Opinions**

*   **Consensus:** Hold
*   **Mean Rating:** 2.92 (~Hold)
*   **Number of Opinions:** 12
*   **Target Price (avg/high/low):** 47.42 / 85.00 / 25.00
*   **Recent Rating Changes:** Not available (indicated by "→ ()")

**Analysis:** The analyst consensus is "Hold," suggesting a neutral outlook. The average target price of $47.42 is below the current price, indicating potential downside risk. The wide range between high and low target prices ($25 to $85) reflects considerable uncertainty among analysts.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue  |
|------------|------|----------|
| 2025-08-04 | 0.19 | 0.54 B$  |
| 2025-05-05 | 0.22 | 0.59 B$  |
| 2024-11-04 | 0.35 | 0.40 B$  |
| 2024-08-05 | 0.06 | 0.32 B$  |
| 2025-08-04 | 0.06 | 0.32 B$  |

**Analysis:**  The trend in both EPS (Earnings Per Share) and Revenue has been generally positive.  Revenue has consistently grown over the past year, and EPS has shown improvement.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-06-30   | $0.54B   | 76.39%        |
| 2025-03-31   | $0.59B   | 73.50%        |
| 2024-12-31   | $0.48B   | 76.81%        |
| 2024-09-30   | $0.40B   | 79.16%        |
| 2024-06-30   | $0.32B   | 81.30%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE     |
|--------------|----------|---------|
| 2025-06-30   | $0.56B   | 7.55%   |
| 2025-03-31   | $0.55B   | 9.01%   |
| 2024-12-31   | $0.48B   | 5.46%   |
| 2024-09-30   | $0.44B   | 17.18%  |
| 2024-06-30   | $0.36B   | 3.67%   |

**Analysis:**

*   **Revenue:** Revenue shows a clear upward trend, indicating strong growth.
*   **Profit Margin:** Profit margins are consistently high, suggesting efficient operations and strong pricing power. There's a slight decline in recent quarters.
*   **Equity:** Equity has been steadily increasing, reflecting the company's growing net worth.
*   **ROE (Return on Equity):** ROE has fluctuated, but remains relatively strong.

**7. Overall Summary**

Hims & Hers Health Inc (HIMS) has demonstrated exceptional growth and outperformance compared to the S&P 500. The company's strong revenue growth, high profit margins, and positive customer feedback are encouraging. However, the high MDD, the analyst consensus of "Hold," and the recent stock price drop raise concerns about potential downside risk.

**Investment Recommendation:**

Based on the information provided, a cautious approach is warranted. While the company shows significant growth potential and recent positive developments (such as expansion of telehealth services), the analyst consensus, recent price drop, and relatively high MDD suggest careful consideration of risk.

**Recommendations:**

*   **Monitor the stock's price movement closely.** Pay attention to news and events that could impact the stock's performance.
*   **Consider a diversified portfolio.** Do not allocate an excessive amount of capital to HIMS.
*   **Long-term investors:** The Hybrid Signal and the expected return of 2% against the S&P 500 is an attractive one.
